FDA Grants Breakthrough Device Designation to MeMed's AI-Powered Infection Test
Key Insights
The FDA has granted Breakthrough Device Designation to MeMed (search) BV Flex™, an AI-powered diagnostic test that distinguishes bacterial from viral infections (search) using capillary blood samples in 15 minutes.
The test measures multiple immune proteins (search) and applies machine-learning algorithms to generate clinically actionable scores, designed for use in hospitals and CLIA-waived settings.
Breakthrough Device Designation provides prioritized FDA review and eligibility for Medicare coverage pathways, potentially accelerating market access and reimbursement.
MeMed (search), a leader in advanced host-response diagnostics, has received FDA Breakthrough Device Designation (BDD) for MeMed BV Flex™, an AI-powered diagnostic test designed to accurately distinguish between bacterial and viral infections (search) using the body's immune response. The designation, announced on March 11, 2026, recognizes the technology's potential to significantly improve the standard of care for patients with infectious diseases.
AI-Powered Diagnostic Innovation
The MeMed (search) BV Flex™ test operates by measuring multiple immune proteins (search) from just a few drops of capillary blood and applying machine-learning algorithms to generate a clinically actionable score within 15 minutes. Running on the MeMed Key™ platform, the system is designed for simplicity and intended for use across hospitals as well as CLIA-waived and decentralized care settings, pending regulatory clearance.
By combining capillary sampling with laboratory-level analytical performance, the technology expands accessibility, particularly for children and elderly patients, while delivering accuracy traditionally limited to central laboratory infrastructure.
Regulatory and Commercial Advantages
Breakthrough Device Designation is reserved for technologies addressing life-threatening or irreversibly debilitating conditions and demonstrating the potential to significantly improve the standard of care. The designation provides prioritized and more interactive FDA engagement, accelerating development and regulatory review processes.
Additionally, BDD provides eligibility to Medicare's New Technology Add-on Payment (NTAP) alternative pathway and Transitional Coverage for Emerging Technologies (TCET). These programs may support broader Medicare coverage, strengthening market access and commercial readiness for the diagnostic platform.
Clinical Impact and Expert Perspectives
Dr. Kristi K. Trimm from TrustCare Health (search) emphasized the clinical significance of the innovation: "This is the kind of diagnostic innovation healthcare has been waiting for. A test that distinguishes between bacterial and viral infections (search) using the body's immune response and AI can help clinicians make more confident decisions, reduce unnecessary antibiotic use, avoid missed bacterial infections (search) and ultimately improve patient outcomes."
The flexibility of capillary sampling and potential CLIA waived status could extend the technology's value beyond hospital systems into urgent care and other frontline settings, helping elevate the standard of care across the healthcare continuum.
Broader Technology Platform
Eran Eden, Ph.D., CEO and Co-Founder of MeMed (search), highlighted the broader implications of the designation: "We are grateful for the FDA's Breakthrough Device Designation, which recognizes the strength of our platform technology and helps streamline our path toward clearance, reimbursement, and ultimately advancing the management of patients with fever (search) and sepsis (search)."
Eden noted that the core technology has applications extending well beyond infectious diseases, with the company's unique ability to integrate machine learning with multiplex host-protein measurements from minimally invasive blood samples opening possibilities across neurology, cardiology, autoimmunity, and other immune-mediated conditions.
Company Background
MeMed (search)'s mission focuses on translating the immune system's complex signals into simple insights that transform disease diagnosis and treatment. The company's MeMed BV® represents the first FDA-cleared host-immune response test for accurately distinguishing between bacterial and viral infections (search) in 15 minutes based on the body's immune response.
The company has also received FDA Breakthrough Device Designation for MeMed (search) Severity™, a host-response test designed to predict severe outcomes up to 72 hours and mortality 14 days in advance in patients with acute infections and suspected sepsis (search), though this product is not yet cleared for sale in any territory.